Sapio Sciences announced a strategic partnership with Ultima Genomics. Together, the companies will deliver efficient, traceable, and unified workflows for multi-omics research and clinical genomics.
The collaboration will make multi-omics workflows more accessible and streamlined for researchers by integrating Sapio’s AI-powered lab informatics solutions with Ultima’s high-throughput, low-cost sequencing platform.
Ultima Genomics is known for its innovative ultra-high throughput sequencing architecture, designed to drive down sequencing costs and scale beyond conventional technologies. Its multiomics sequencing capabilities allow researchers to study layers of biology beyond DNA sequences alone. Many changes linked to disease occur first in other omic layers, such as in the epigenome with cancer.
Deeper levels of analysis are increasingly important for understanding complex biology, but until now have often required multiple costly assays and fragmented workflows. This integration allows researchers and clinicians to combine Ultima’s data generation capabilities with Sapio’s analytics, automation, and data management tools for a seamless, end-to-end solution.
Key benefits:
- Integrated workflows: Unify sequencing and informatics into a single environment, so researchers avoid fragmented assays.
- Lower cost per sample: Reduce per-sample costs with ultra-high throughput sequencing.
- Faster discovery cycles: Accelerate discovery cycles with AI-driven analytics and automation.
- Improved traceability: Ensure compliance through end-to-end data provenance tracking.
- Future-ready architecture: Support genomics, transcriptomics, proteomics, and other omics fields with a future-ready architecture.
Visit Sapio Sciences for more information
